Patent Term Extension Application for ENCELTO (revakinagene taroretcel-lwey), Patent No. 10,195,140 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-1672

Patent Term Extension Application for ENCELTO (revakinagene taroretcel-lwey), Patent No. 10,195,140

Documents

Comments

Description

OPEN

Comment Period OpensJun 17, 2025

Comment Period ClosesJun 3, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO FR Doc: 2026-06477	Apr 3, 2026	--

CDER

Patent Term Extension Application

Fenwick & West LLP

Neurotech USA, Inc.

ENCELTO (revakinagene taroretcel-lwey)

Patent No. 10,195,140

OPEN